Selected article for: "angiogenesis inhibition and cardiovascular disease"

Author: Zhong, Jixin; Rajagopalan, Sanjay
Title: Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
  • Document date: 2015_9_25
  • ID: 0nqmjdek_17
    Snippet: FiGURe 1 | Dipeptidyl peptidase-4 inhibition in modulation of SDF-1 and myocardial angiogenesis: expression of DPP4 increases in myocardial infarction. Suppression of DPP4 enzymatic activities by pharmacological inhibitors preserves SDF-1, which results in an enhanced homing of CXCR4 + progenitor cells from bone marrow to infarcted tissues. CXCR4, chemokine (C-X-C motif) receptor 4; DPP4i, DPP4 inhibitor; MI, myocardial infarction; SDF-1, stromal.....
    Document: FiGURe 1 | Dipeptidyl peptidase-4 inhibition in modulation of SDF-1 and myocardial angiogenesis: expression of DPP4 increases in myocardial infarction. Suppression of DPP4 enzymatic activities by pharmacological inhibitors preserves SDF-1, which results in an enhanced homing of CXCR4 + progenitor cells from bone marrow to infarcted tissues. CXCR4, chemokine (C-X-C motif) receptor 4; DPP4i, DPP4 inhibitor; MI, myocardial infarction; SDF-1, stromal-derived factor-1. DPP4 in chemotaxis and cardiovascular disease Frontiers in Immunology | www.frontiersin.org

    Search related documents:
    Co phrase search for related documents
    • bone marrow and cardiovascular disease chemotaxis: 1
    • bone marrow and enhanced homing: 1
    • bone marrow and enzymatic activity: 1, 2, 3
    • bone marrow and myocardial angiogenesis: 1
    • bone marrow and myocardial infarction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • bone marrow and pharmacological inhibitor: 1
    • bone marrow and progenitor cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • bone marrow progenitor cell and cardiovascular disease: 1
    • bone marrow progenitor cell and progenitor cell: 1, 2, 3, 4, 5
    • cardiovascular disease and enhanced homing: 1
    • cardiovascular disease and enzymatic activity: 1, 2, 3, 4, 5
    • cardiovascular disease and myocardial angiogenesis: 1
    • cardiovascular disease and myocardial infarction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiovascular disease and pharmacological inhibitor: 1
    • cardiovascular disease and progenitor cell: 1, 2, 3, 4
    • cardiovascular disease chemotaxis and enhanced homing: 1
    • cardiovascular disease chemotaxis and myocardial angiogenesis: 1
    • cardiovascular disease chemotaxis and myocardial infarction: 1
    • cardiovascular disease chemotaxis and progenitor cell: 1